Evoke Pharma, EVERSANA expand GIMOTI access with Omnicell relationship

Evoke Pharma (EVOK) together with EVERSANA announced the addition of Omnicell (OMCL). This relationship is expected to expand patient access to GIMOTI, the only FDA-approved nasal spray for adults with acute and recurrent diabetic gastroparesis specifically, into large gastroenterology organizations. As part of Evoke’s strategy to broaden GIMOTI’s reach through key pharmacy partnerships, the addition of Omnicell is meant to ensure better alignment with specialty pharmacies used by large gastroenterology group practices, like Gastro Health, which has a presence in 7 states and 150 locations. This relationship is expected to almost double the number of specialty pharmacies available to access Gimoti.